论文部分内容阅读
奥沙利铂是第3代铂类抗癌药物,与前2代铂类抗癌药物相比,在肾毒性、耐药性、蛋白结合率等方面均有较大改善。近年来,奥沙利铂在胃癌等多种恶性肿瘤的化疗应用中日益广泛,其药物不良反应也逐渐引起人们重视。本文报道1例胃癌患者予静脉滴注(静滴)奥沙利铂期间猝死,并对相关文献进行复习。病例资料患者,男性,年龄55岁,于2009年11月出现间断性腹胀、腹痛,疼痛无放射,无恶心、呕吐,无呕血
Oxaliplatin is the third generation of platinum anticancer drugs, compared with the first two generations of platinum anticancer drugs in the nephrotoxicity, drug resistance, protein binding rate and so on have greatly improved. In recent years, oxaliplatin has been widely used in the chemotherapy of gastric cancer and other malignant tumors, and its adverse drug reactions have gradually attracted people’s attention. This article reports a case of gastric cancer patients to intravenous infusion (intravenous infusion) of oxaliplatin during sudden death, and the relevant literature review. Case Information Patients, men, aged 55 years old, developed intermittent abdominal distension, abdominal pain, pain without radiation, nausea, vomiting and no vomiting in November 2009